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Rethinking animal models of sepsis – working towards improved clinical 
translation whilst integrating the 3Rs 
Abstract 
Sepsis is a major worldwide healthcare issue with unmet clinical need. Despite extensive animal 
research in this area, successful clinical translation has been largely unsuccessful.  
We propose one reason for this is that, sometimes, the experimental question is misdirected or 
unrealistic expectations are being made of the animal model.  
As sepsis models can lead to a rapid and substantial suffering – it is essential that we continually review 
experimental approaches and undertake a full harm:benefit impact assessment for each study. In some 
instances, this may require refinement of existing sepsis models. In other cases, it may be replacement 
to a different experimental system altogether, answering a mechanistic question whilst aligning with 
the principles of reduction, refinement and replacement (3Rs).  
We discuss making better use of patient data to identify potentially useful therapeutic targets which 
can subsequently be validated in preclinical systems. This may be achieved through greater use of 
construct validity models, from which mechanistic conclusions are drawn. We argue that such models 
could provide equally useful scientific data as face validity models, but with an improved 3Rs impact. 
Indeed, construct validity models may not require sepsis to be modelled, per se. 
This paper asks the reader to move away from the bench to bedside forward translation approaches 
and move towards a bedside to bench reverse translation approach, carefully considering the most 
appropriate model whilst prioritising the 3Rs. This in turn may improve chances of successful clinical 





What is the clinical need?  
Sepsis arises from a dysregulated host response to a microbial infection and can lead to septic shock. 
Patients with this syndrome experience circulatory, cellular and metabolic abnormalities which can lead 
to life threatening organ dysfunction [1]. Meaningful global mortality estimates are difficult to 
ascertain, and research is often limited to reporting from high income countries, but it remains a leading 
cause of death and critical illness worldwide [2, 3]. Short-term mortality has been estimated at 45-50% 
and half of those that go onto survive may have subsequent long-term decline with about one in six 
survivors dying within a year[4-6].  
It has been argued that earlier diagnosis of sepsis will have the greatest impact on patient outcome and 
reduce the economic burden on the healthcare provider [7, 8]. Earlier diagnosis allows clinicians to 
treat and manage the underlying infection using standard approaches (including source control and 
antimicrobial therapy) and to anticipate or manage cardiovascular instability and other evolving organ 
dysfunction [9, 10]. The later the diagnosis, the more complex clinical management becomes, with a 
rapid rise in mortality risk and ongoing complications for survivors [11].  
Another argument highlighted in this context is that knowledge of different sensitive and specific 
serological and physiological biomarkers and the development of early warning scores and multi-
biomarker algorithms may aid in identifying and stratifying patients and assist clinicians in planning 
investigation and  treatment, and in particular identifying those at the highest risk [6, 12-16]. In 
addition, understanding certain known or yet to be discovered biomarkers could lead to the 
identification of therapeutically useful new targets or diagnostic approaches, which may need to be 
validated using non-clinical systems.  
Clinical manifestations of sepsis are protean, risk of adverse outcome and response to treatments also 
vary between patients. The trajectory of illness progression and recovery from sepsis in humans has 
also not been well studied. Thus, given that there is no single trajectory of sepsis progression, treatment 
or resolution in humans – there are significant challenges with meaningfully modelling the clinical 
syndrome in research animals. 
In the Table 1, we summarise certain current clinical needs and research approaches that could address 




Table 1: Current clinical need and where research animals fit in 
Clinical need Research approach Does this necessitate the use 
of research animals? 
Effective antimicrobial agents 
Immunological modulators 
Inflammatory modulators 
Agents to treat common 
symptoms with improved 
efficacy/safety profile  
e.g. coagulopathy, myocardial 
dysfunction, delirium 
Demonstration of target 
engagement and safety. 
Identification of detailed 
biomarkers associated with on-
target efficacy and/or safety - 
to inform future conduct of 
clinical trials  
Yes – where there is no 
alternative. 
We propose studies should 
be mechanistic in nature (see 
Table 2) 
As above  Drug repurposing Less likely – regulatory safety 
pharmacology, toxicology 
and pharmacokinetic studies 
completed. 
Biomarkers corresponding to 
beneficial/detrimental responses 
to existing treatment.  
Biomarkers facilitating diagnosis 
Biomarkers/modifiable elements 
facilitating patient stratification 
into risk groups 
Information gained from better 






What is the preclinical problem? 
In the context of preclinical sepsis research, there has been a poor clinical translation of therapeutic 
entities validated in animal models of sepsis. Blame for the widely reported translational ‘valley of 
death’ [17] is often placed at the feet of pre-clinical researchers for using flawed animal models or for 
inappropriate experimental design and/or reporting. Whilst these are valid arguments, we propose that 
another reason for lack of translational impact is that, in some cases, current pre-clinical animal models 
are not capable of answering the experimental question being asked. Where the question is ‘will my 
putative treatment provide clinical benefit to sepsis patients’, we would argue that most current animal 
models cannot provide a meaningful, predictive answer.  
Translational paradigms of “bench to bedside strategy” may have been inappropriately applied - 
particularly when aiming to model complex multi-system conditions like sepsis. Bedside to bench and 
back -  where clinical data helps to define specific targets or probe specific mechanisms, may prove 
more fruitful.  
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From a research perspective, it is imperative that preclinical scientists engage with clinicians to 
understand the clinical need. Additionally, wider interdisciplinary collaboration (bioengineering, 
epidemiology, statistics) can ensure that: 
• the right targets/strategies/pathways are identified and studied based on clinical precedence 
through available human data 
• the most appropriate experimental systems and endpoints are being used to validate the value 
of investigational therapeutic entities and biomarkers 
• new and improved data acquisition and analysis/statistical techniques are being used to 
improve quality of results, whilst impacting positively on research animals 
• realistic interpretations are being made of the preclinical data, avoiding ‘over translation’. 
How animals are currently used in sepsis research – ethical and translational issues 
There are two main categories under which research animals are used in the context of sepsis research: 
1) to understand the mechanism of sepsis syndrome progression and identify involvement and 
changes in physiological, molecular and/or cellular pathways  
2) to assess the efficacy/safety/pharmacokinetics of therapeutic targets/agents for proof of 
concept or regulatory studies  
To date, sepsis and septic shock modelling methods have either involved administration of an 
inflammatory trigger (e.g.  endotoxin), a microbial trigger (e.g. bacterial or peritonitis models) or co-
morbidity models (e.g. trauma plus infection). All these models have the potential to cause significant 
suffering, if conducted in conscious animals.  
Justification for the use of any particular model must always have a clear scientific rationale and this by 
extension, should include a full harm:benefit impact assessment. In this context, ‘harm’ refers to the 
experience of the animal during the experiment (or indeed over the lifetime of the animal if the 
legislative framework requires this) whilst ‘benefit’ relates to the scientific value of data generated from 
the study. 
Of key importance is the fact that animal models of sepsis can lead to mortality, which is still used today 
as an experimental end point. Given the historically poor translation of animal models of sepsis, use of 
mortality as an end point is becoming increasingly difficult to ethically and scientifically justify from a 
harm:benefit perspective.  However, progress is being made here, for example the Galleria mellonella 
moth larvae could represent a replacement for mammalian models where survival endpoints are 
needed – providing a rapid efficacy screening tool for novel antimicrobial agents [18]. 
Whilst efforts are being made to reach consensus on what constitutes experimental sepsis (in 
mammals) in order to standardise the scientific literature [19], it is not the purpose of this paper to 
critique different ‘sepsis syndrome’ modelling approaches.  Furthermore, recommendations have 
already been published on how to optimise animal welfare within such models [19, 20] and will not be 
discussed in detail. However, in this paper we will consider how we might rethink our use of animal 
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systems in sepsis research to enhance the translation gap and by extension impact positively on the 
application of the 3Rs principles. 
Why do preclinical sepsis models translate poorly?  
It is well recognised that no single animal model can recapitulate the complex and varied clinical 
manifestations of the sepsis syndrome and there are clear differences between what is modelled in 
research animals and what is seen in patients. Nevertheless, we argue that as long as a harm:benefit 
analysis has been conducted and that realistic interpretations are being made of the data, such 
experiments can still be of scientific value, especially with regard to furthering the understanding of the 
underlying pathophysiology and identification and validation of novel therapeutic and diagnostic 
approaches. 
Common criticisms of many animal model of disease, include the use of single sex, young animal 
cohorts, typically influenced by cost, time and infrastructure limitations as well as a desire to total limit 
animal numbers in line with the 3Rs.  Introduction of experimental bias through lack of randomisation, 
blinding or inappropriate statistical analysis is also commonly criticised in many animal models (and 
research in general)  but reassuringly, initiatives in education and transparency coupled with planning 
and reporting guidelines from  scientific journals and research funders, may lead to improvements [21-
25] 
 
Criticism of sepsis models per se, have focused on questionable experimental time courses, including 
the duration of the ‘sepsis syndrome’, choice of end points or the length of follow up in survivors - 
which do not necessarily correspond to the clinical situation. It has been argued that the duration of 
follow up  is often too short and may not capture the more persistent changes in the inflammatory 
response that ensue in patients [26, 27]. However, performing longer-term sepsis studies in animals 
has the potential to increase the welfare burden and this requires careful consideration of harm vs. 
benefit. Indeed, it is still not known whether extending such studies in animals will improve our 
understanding of, or better predict, longer-term outcomes in patients. 
Studies have also been criticised for timing of interventions. Here the research question and the context 
in which the data is interpreted is key. One argument is that pre-treatment with a new therapeutic 
entity does not reflect the projected clinical use, where such agents would be administered after 
symptom development. However, ‘pre-treatment’ studies may be scientifically valid, if a mechanistic 
research question is being asked and mechanistic conclusions are drawn. Indeed, for studies involving 
genetically altered animals, these would typically have a pre-existing change in the gene product 
expression (e.g. a knockout). This approach is scientifically valid as a proof of concept study to 
demonstrate the relationship between a gene product and its impact on one or more biological 
pathways that may become dysregulated during inflammation/infection. It does not, however, provide 
direct evidence as to whether the target is therapeutically useful in sepsis patients, as the study was 
not designed to test this. This highlights the onus on scientists to carefully define their experimental 
Take home message :  
Experimental sepsis research must be designed, conducted and reported in such a way to 
minimise bias and to maximise the potential for replication 
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question and accurately interpret the results. Similarly, journal reviewers and editors should ensure 
data is interpreted in the context of the mechanistic question, avoiding over optimistic data 
interpretation or ‘over translation’.  
Another criticism is the lack of routine supportive therapies such as antimicrobial, fluid resuscitation 
and other supportive interventions that are not routinely incorporated into models. We will discuss this 
issue later in the ‘Animal ICU section’. 
 
Homogeneity versus heterogeneity; face vs. construct validity  
A key difference between the hospital and laboratory setting is the greater homogeneity of 
experimental animal systems compared to the highly heterogenous clinical population. Homogeneity 
can be considered an experimental necessity as it enables an investigator to assess the difference 
between two treatment groups – carefully controlling confounding factors. However, the expected 
lower variability in inter-animal responses could lead to a relatively modest effect size to be deemed 
statistically significant. In turn, this could lead to over interpretation and misdirected prediction of the 
potential clinical impacts [28].  
In contrast, there is extremely high patient heterogeneity in the clinical setting, where sepsis affects 
neonates through to elderly co-morbid patients. Differences in the patient demographics, infection 
source(s), route of entry etc. all lead to complex variability in both the syndrome progression and in 
responses to clinical interventions. The ability to detect clinically meaningful effects of new therapeutic 
entities, on the background of such variability becomes highly challenging. Arguments have been made 
as to why trials fail so frequently and to perhaps rethink clinical trial design, including improved 
stratification of trial participants into phenotypic groups, more detailed biomarkers as endpoints and 
the use of adaptive trial design [29, 30].  
It has been suggested that more heterogeneous animal models e.g. using outbred strains [31], 
modelling comorbidities  or introducing changes in husbandry moving away from a highly controlled 
pathogen free environment [32, 33], may address issues of reducing homogeneity in animal studies. 
However, this could lead to ‘uncontrolled heterogeneity’ which could make experimental interpretation 
and clinical translation, more difficult. Methods to systematically introduce heterogeneity [34] may be 
helpful but would require infrastructure changes to facilitate this.  
Whilst on one level, making experimental systems “look” more like the heterogeneous clinical 
population (face validity), may appear sensible, it may not necessarily improve clinical translatability of 
the results. It would also likely necessitate larger groups of animals in order to demonstrate meaningful 
effect sizes, going against the principle of the ‘R’ of reduction.  
Take home message :  
Harm-benefit impact assessment and full scientific justification should be at the forefront of any 
new studies involving research animals. Data should be interpreted in the context of what the 
model can deliver, avoiding over optimistic translation. 
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We propose that an alternative approach would be to ask more mechanistic questions (construct 
validity) of the experimental systems[35].   For example if a plasma biomarker is essential, it may be 
sufficient to show target engagement of a test compound, as reflected by a change in a biomarker 
coupled with corresponding test compound plasma concentration levels,  as opposed to demonstrating 
an impact of that compound on sepsis syndrome progression. This approach avoids some of the 
predictive validity issues associated with disease models, with the potential to reduce the welfare 
burden for animals [35].  
Indeed, it has been argued that target engagement, exposure at the site of interest, and some 
indication of pharmacological activity (described as the ‘three pillars of survival’) is adequate for phase 
II clinical trials [36]. We would argue that pre-clinical assessment of efficacy in animals could be 
approached in the same way – especially given the historically poor clinical translation of sepsis models 
data. 
Research to further our fundamental understanding of the dysregulated immune response that occurs 
in sepsis is still needed - and this may still require research animals. However, we would argue that 
these studies should also have a mechanistic focus and results should be interpreted within this context. 
Indeed, the fundamental immunological and molecular signalling differences between humans and 
common laboratory animals, highlight the experimental challenges [37, 38]. Such insights might be 
better gleaned from analysis of increasingly available clinical electronic health record data. 
In summary, mechanistic studies may still utilise existing models of sepsis, but with more careful 
consideration of time courses, biomarker measurements and avoiding death as an endpoint. This 
approach could still address important scientific questions whilst  impacting  positively on the predictive 
validity of the model and welfare of the research animal [39] (Table 2). 
 
Take home message : Construct validity and the 3Rs 
Focusing on construct rather than face validity, has the same potential to increase clinical 
translation, but with reduced levels of animal suffering. 
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Table 2: A comparison of disease models (face validity) with mechanistic models (construct validity) and 







A major theme of this review is the proposal that pre-clinical sepsis research can be better served 
using mechanism-based models rather than phenotypic-disease models. To clarify what we mean by 
this let us give our definition of these two approaches. 
Disease model 
An in vivo disease model is one where, via surgical, chemical, biological or genetic intervention, an 
animal displays a phenotype that looks like (has high face validity) one or many aspects of the 
equivalent human disease. Such a model will typically use a disease score or a surrogate to a human 
clinical outcome measure (e.g. mortality in sepsis) as a primary experimental endpoint. For example, 
the rat collagen-induced arthritis model [40] involves immunization with type II collagen which can 
lead to severe arthritis with bone matrix resorption, considerable soft tissue swelling, periosteal new 
bone formation and bone erosion.  
Mechanistic model 
A mechanistic model (with high construct validity) is optimised to provide a robust signal-to-noise 
ratio for engagement (activation or inhibition) of a specific target mechanism. This may or may not 
involve an animal, but the advantage of an in vivo mechanistic model is the possibility of concurrent 
measurement of the plasma level of pharmacological interventions or biomarkers. Such a model can 
share similar induction methodology as a disease model, but importantly has specific mechanism-
based endpoints rather than phenotypic endpoints, for example the concentration of a specific 
plasma biomarker.  
Alternatively, the mechanistic model may have little similarity to the disease of interest, providing 
the mechanism being studied is the same, and the signal-to-noise ratio is optimised. For example, a 
drug discovery program based on a hypothesis (derived from human clinical genomic data) that 
inhibition of a specific cytokine would be beneficial in rheumatoid arthritis. The key information 
required for progression of a new drug into clinical development is adequate target engagement at 
a given plasma level (how much drug is required to inhibit the action of the cytokine). This 
information can be obtained from any in vivo model where the biological activity of the cytokine can 
be measured, and this does not have to be a model of arthritis per se.  
For both types of model, a full harm:benefit impact assessment should ensure the appropriate animal 
model with lowest welfare concern for highest scientific value, is chosen. 
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What needs to change? Part 1 - Focus on improving mechanistic insight of 
sepsis pathophysiology  
Isolating particular features of the clinical condition may help to develop more mechanistic models 
which may prove useful in answering discrete biological questions. Indeed, the sepsis syndrome can be 
broken down into a series of key features. We will explore some of these in more detail below. 
Immune Dysfunction 
The central importance of the immune system in sepsis has prompted the search for specific therapies 
targeting the immune response. However, despite considerable research effort with experimental 
models and numerous clinical trials, there are no immune-based treatments for sepsis in current 
routine clinical use. This failure highlights the disconnect between existing experimental models of 
sepsis and the complex disease in human patients. In particular, the lack of translation between highly 
inbred mouse strains with specific infective foci and the considerable heterogeneity of the sepsis-
induced immune response both between patients and within individuals over time [39] [41, 42] . Such 
heterogeneity suggests that any single treatment strategy will not succeed and that a personalised 
medicine approach is required. Therefore, it is likely that the success of future trials of sepsis therapies 
will rely on precision medicine approaches, with a focus on underlying immune responses in patients. 
Mechanistic models of the immune dysfunction in sepsis are thus required to support the development 
of new immune-targeting therapies and to identify biomarkers to monitor the immune status and guide 
treatment.  
 
At present, immune status is derived from plasma markers or expression of molecules on circulating 
blood cells. However, the immune response is highly compartmentalised and varies over time and the 
phenotype of circulating blood cells may not be the best indicator of current immune status. Existing 
animal models of sepsis often show enhanced cytokine production despite having profound leukopenia 
suggesting blood immune cells have a limited role in producing inflammatory mediators for host 
defence[43]. Moreover, murine experiments have shown that blood and spleen leukocytes become 
hyporesponsive by endotoxaemia or caecal ligation and puncture-induced sepsis (i.e. tolerance) [44] 
but the functions of macrophages from different tissues and organs was found to be either unaffected 
or primed [45] [46]. In healthy volunteers given endotoxin, alveolar macrophages are primed for 
increased inflammatory cytokine production whereas blood monocytes are shown to be profoundly 
immunotolerant [47]. These and other findings in human models of endotoxaemia suggest that 
compartments other than blood, shape the immunosuppression in sepsis [47]. Nevertheless, the 
‘tolerance’ induced by endotoxin in human volunteers shows many similarities to sepsis-induced 
immunoparalysis including decreased cytokine production by circulating leukocytes. Endotoxin 
tolerance has therefore been used as a model to investigate treatments for sepsis-induced 
immunoparalysis, both in vitro [48]  and in vivo in humans [49]. In contrast, however, animal studies 
have shown that despite a reduced immune response, pathogen clearance and survival after live 
bacterial challenge were enhanced in mice pretreated with LPS or other TLR ligands [50]. It is unknown 
whether the same pathogen clearance effect would be seen in humans and this could be studied in 
future trials. New experimental models that report on the tissue immune response are thus urgently 
required to improve our understanding of the mechanisms of the immunological response during sepsis 
and to guide the use of immune-modulating therapies.  
10 
 
Platelets are another blood immune cell implicated in the excessive inflammatory host response during 
sepsis which can be both pro- and anti-inflammatory/thrombotic in nature. Correlations have been 
observed in the ICU between platelet number and mortality rates with low platelet count 
(thrombocytopenia) correlating with poor outcome [51-53]. This has prompted studies to evaluate the 
potential benefits of platelet therapy in sepsis [54]. Therefore, preclinical models will continue to be 
required to provide a better understanding of the mechanisms behind this role of platelets in the sepsis 
syndrome. 
 
A more accurate picture of the in vivo immune response will also likely require a panel of biomarkers 
that reflect the immune response in different compartments and at different times. Many current 
biomarkers, such as circulatory inflammatory cytokines are prognostic rather than diagnostic in value. 
Others have a high sensitivity but low specificity (CRP) and may not distinguish between 
hyperinflammatory states and immunoparalysis (procalcitonin). Potential markers of immunoparalysis 
are proposed from patient studies including expression of inhibitory receptors like programmed death-
1 (PD-1) its ligand PD-L1 and cytotoxic T lymphocyte antigen-4 (CTLA-4)[55]. In addition, suppressor 
lymphocyte populations (T-regs) have been linked to patients with immunoparalysis [56]. 
 
Identifying and understanding the causes of hyperinflammation and immunoparalysis in sepsis patients 
is the key to developing effective immune-based therapies. Interestingly, meta-analysis and post hoc 
analyses of data from the many ‘failed’ trials of anti-inflammatory agents have revealed that such 
therapies may have been effective in sub-groups of patients [57]. This again highlights the need to 
stratify sepsis patients according to defined sub-groups so they receive the most appropriate therapy.  
 
Systems Biology 
Advances in our mechanistic understanding of susceptibility to adverse sepsis outcomes may come 
from human patient studies and replace traditional experimental animal models. The development of 
translational high throughput methods and analysis tools has allowed the identification of distinct 
subgroups based on host response to sepsis. These subgroups or ‘endotypes’ will allow for patient 
stratification to target the most effective therapies. Transcriptomic profiling of sepsis patients has 
defined different sepsis response types which could be linked to immune suppression, metabolic 
derangements 14 day mortality [58].  Significantly, these response endotypes could be accurately 
predicted from 7 genes. Interestingly, a different study identified the same endotypes in fecal 
peritonitis patients with similar outcomes [59]. A comprehensive transcriptomic profile of 700 sepsis 
patients revealed 3 sub groups – the one with the highest mortality and reduced adaptive immunity 
corresponding to the most susceptible group defined in the earlier studies [60].  Such profiling should 




Observations in mammalian models of vaccination which found that protection from reinfection 
occurred independently of T and B lymphocytes led to the hypothesis that innate immunity can display 
characteristics of adaptive immunity in response to pathogens or their products and has been coined 
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“trained immunity”. The discovery of trained immunity allows the opportunity to develop models to 
evaluate the effects of immune training on sequelae and outcomes in polymicrobial sepsis and the 
impact of immune training in the prevention and/or treatment of sepsis-induced immune paralysis and 
organ injury [61]. Interestingly, trained immunity also provides a mechanistic link between sepsis and 
atherosclerosis that has been observed in animal models of sepsis [62].  
Metabolic switching 
Growing evidence supports that metabolic changes underlie immune responses including the immune 
cell phenotype in sepsis [63]. Indeed, LPS activation of TLR4 signalling pathways is associated with 
switching to glycolytic metabolism in the activation of macrophages. These changes in glucose 
metabolism mirror the immune responses seen in septic patients with a switch from a more transient 
hypermetabolic anabolic state to a hypometabolic state in cell, animal, and human models of sepsis. 
Sirtuins (SIRT) play a crucial role in this metabolic switch coincident with the switch from hyper to hypo 
inflammatory response and several animal model studies show the mechanistic benefit of targeting 
sirtuin-1 in sepsis  [64, 65].  
 
The HIF signaling pathway has gained significant importance as a possible immunometabolic switch and 
HIF has been proposed as a sepsis biomarker and therapeutic target [66]. Indeed, it was recently shown 
that myeloid HIF-1 plays an acute time dependent role in regulating the peripheral glycolytic response 
[67]. Mechanistic studies using human cells from patients and different animal models will provide a 
more clinically relevant understanding of the metabolic alterations which occur in innate immune cells 
and the role of HIF signaling [66]. 
 
The Inflammasome 
Further improvements to the translational value of sepsis models will likely come from a better 
understanding of the mechanisms of innate immune responses to infection. One such area of intense 
research is the inflammasome. The best characterized is the NLRP3 inflammasome, that also contains 
adapter protein apoptosis-associated speck-like protein (ASC) and procaspase-1 that activates the 
inflammatory cytokines IL-1b and Il-18 and induces a form of cell death known as pyroptosis [68]. 
Recent studies demonstrate that NLRP3 inflammasome-related molecules (e.g., NLRP3 and ASC) are 
critically involved in the acute inflammation and tissue injury involved in the pathogenesis of CLP-
induced polymicrobial sepsis. Inflammasome dysfunction is a recognized feature of sepsis-induced 
hyperresponsiveness [69] and growing evidence suggests that inflammasomes play a critical role in 
bacterial infections [70]  [71]. NLRP3 inflammasomes interact with many molecules associated with a 
variety of conditions. For example, an overactivated NLRP3 inflammasome in immune cells is associated 
with both obesity and insulin resistance and T2DM. Therefore, it is possible that pre-existing 
dysregulated inflammasome function may predispose patients to sepsis from an infection that could be 
overcome in otherwise healthy persons [72]. Drugs designed to target NLRP3 inflammasome activation  






The human model of the immune response in sepsis 
The immune response is sepsis involves the complex interplay of thousands of genes in a ‘genomic 
storm’ [75]. Such complexity and heterogeneity suggests that any single animal model may not be 
appropriate and any single sepsis therapy therefore likely unachievable. Research in sepsis is currently 
shifting away from models that cannot accurately reflect the human condition towards a mechanistic 
understanding of the complex pathways in the sepsis process. Understanding how these pathways 
interact may lead to the identification of common targets that can affect downstream signaling events. 
 
Development of human models of the immune response will better aid the translation of fundamental 
mechanistic studies and include ex vivo and in vitro studies of human immune cells directly, including 
from blood and tissues. Studies using peripheral blood are valuable due to the relative ease of acquiring 
samples and the potential for future translation in diagnostics and immunotherapies. Human challenge 
models, in which healthy subjects are infected with a controlled amount of microorganism or their 
components, will also provide relevant mechanistic data. Furthermore, new systems biology tools will 
allow the high throughput of human-derived data, which has been the advantage of current animal 
models [76]. Development of more sophisticated models allowing more detailed knowledge of the 
human immune system in sepsis will enable the identification of new immune mechanisms that can be 








Take home message : Immunological and metabolic  
 
As our knowledge of the innate immune responses in sepsis increases, new therapeutic targets 
and new potential biomarkers to measure sepsis progression and response to therapy are 
emerging. These include metabolic markers that underlie trained immunity and immune cell 
activation and biomarkers of inflammasome activation which could be mechanistically 
investigated in preclinical models. As tools and technologies for systems biology and high 
throughput screening advance, there can be an increased use of humans and human –derived 
tissue for sepsis research models. Development of more sophisticated models will enable the 





Circulatory disturbances form a hallmark of sepsis (septic shock) and circulatory shock is associated 
with increased mortality rates [77]. Given the lack of clinically available immunomodulatory therapies, 
current patient treatment focuses on control of the source of infection, (draining or releasing any focus 
where possible), antimicrobial therapy and empirical hemodynamic support.  
Clinical recommendations are in place regarding hemodynamic support for  patients including fluid 
support, vasopressor and cardiac inotrope administration of well characterised agents [10]  . However, 
optimising and managing hemodynamic support strategies in sepsis patients is not always 
straightforward. Nevertheless, it could be argued that a key clinical need, is a mechanism to facilitate 
optimisation of individual patient dosing regimens for escalation and de-escalation of treatment [78]. 
Such information could be better identified through retrospective clinical data, rather than from further 
animal experimentation. Use of retrospective patient data would allow specific regimens and to be 
linked to patient outcomes and could reveal specific patient signatures that associate with 
advantageous vs. disadvantageous responses to treatment. The clinical benefit of such signatures 
would, of course, require validation using a prospective randomised controlled trial. However, if 
validated, such information could be consolidated into clinical decision support tools and scoring 
systems. This type of research will necessitate an interdisciplinary approach to data collection, 
annotation, analysis and interpretation, but proof of concept studies already exist [79] [80]. 
 
Fluid resuscitation 
Relative hypovolaemia is common in patients with sepsis and leads to reduced cardiac preload resulting 
in reduced cardiac output and systemic oxygen delivery. Fluid is administered during resuscitation to 
replace the fluid deficit to augment cardiac filling and cardiac output. Clinically, fluid resuscitation in 
patients can be guided by hemodynamic and biochemical variables and there are international 
recommendations in place[10]. In small animal studies (mice, rats), the continuous assessment of such 
variables is not as always feasible, but is possible in larger species such as pigs [81]. As with humans, 
fluid resuscitation regimes have been investigated in animal models with certain regimes improving 
hemodynamic variables and outcomes [82, 83]. Later we will discuss the concept of ‘animal ICUs’ 
allowing intensive investigation of individual trajectories from anesthetised, fluid resuscitated, 
preparations. 
Scientists who wish to model hyperdynamic changes in research animals require effective fluid 
resuscitation. For small lab species such as mice and rats, this can be technically challenging to perform 
and fluid overload can easily occur, resulting in inadvertent oedema. However, hyperdynamic rodent 
models do exist [84, 85] [86]. From a welfare perspective, high volume resuscitation should be 
conducted via indwelling vascular access ports [87] which facilitates continuous or multiple infusions. 
However, intra peritoneal or subcutaneous resuscitation tend to be more commonly performed as 
single boluses  [20]. The varied nature of fluid resuscitation (e.g. crystalloid vs. colloidal, continuous vs. 
bolus), and the extent to which animals are resuscitated in different labs, can greatly influence 
commonly measured parameters such as blood pressure, cardiac output and ejection fraction. 
Furthermore, normalised or delta changes, in such parameters, are often reported in the literature, 
making it challenging for the scientific community to have a grasp of the absolute degree of change 
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anticipated within a model. Recommendations for the nature of resuscitation have been generated and 
this may assist in standardising how such experiments are conducted [88]. Whether this improves 
clinical translation of new therapeutic entities, still remains to be determined.  
Cardiac and circulatory disturbances – in vivo and in vitro 
One of the benefits of preclinical sepsis experimentation, is that the exact time of the infection (t=0) is 
known, allowing time dependent changes to be accurately mapped. Cardiac and circulatory 
disturbances are a hallmark feature of many animal models of sepsis, and mechanistic studies may 
involve investigating the effects of gene product modifications or new therapeutic entities on the 
trajectory of cardiovascular dysfunction and tissue perfusion, following infection. Depending on the 
research question, such studies could be conducted in either conscious or anesthetised animals. 
Animal models of sepsis or endotoxaemia have been shown to display many cardiovascular 
disturbances that correspond to those seen in patients and human volunteers [89-91] . These include 
tachycardia, tachypnoea, cardiac dysfunction [92],  vasodilatation and hypotension [93, 94], pulmonary 
hypertension [95] increased incidence of arrythmias [96]  microcirculatory disturbances and time 
dependent changes myocardial function and regional tissue perfusion, oxygenation and end organ 
damage [97, 98]. There are however certain fundamental differences between humans and common 
lab animals, such as non-shivering thermogenesis, observed in mice [99]. Whilst many concerns have 
been raised as to the translatability of murine sepsis models, this is still a commonly used species for 
mechanistic studies, given the relative ease of genetic alteration.   
Importantly, as discussed earlier, it may not always be necessary to model sepsis per se and, where 
possible, those mechanistic models which pose the lowest welfare burden should be used.  At a cellular 
level, it has been established that microvascular endothelial damage can be aggravated by 
inflammatory mediators, generated following a host response [100]. It is technically challenging to 
isolate cellular effects from whole animal systems, although endothelial specific gene modification and 
microvascular perfusion measurements are feasible and may provide useful information. 
However, advances have been made with in vitro replacement models, such as organ-on-chip systems 
which might help scientists understand endothelial and smooth muscle cell functionality and 
interactions in mechanistic models of inflammation and could provide a surrogate system to 
understand gene product or pharmacological effects [101]. 
Cardiovascular monitoring technologies that support refinement. 
Most routine cardiovascular clinical measures can be quantified without necessitating significant 
restraint or human intervention, thereby reducing stress responses. These include blood pressure, 
temperature, ECG and locomotion radiotelemetry, using implantable devices that enable real time 
monitoring of animals in their home cages. Solitary isolation can be limited via cohousing with 
unimplanted animals or with implanted animals transmitting data at a different frequency [102]. 
Telemetry probe implantation surgery does pose a welfare burden, with animals typically requiring 7-
10 days recovery time, before readings can be taken. Non-invasive echocardiography can capture more 
nuanced information about cardiac function and can be conducted in telemetered animals. 
Echocardiography is typically conducted under anaesthesia so repeated measures are possible, but this 
can become challenging, especially in the later stages of the sepsis syndrome, when animals are more 
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compromised and physical restraint/anaesthesia can increase the welfare burden. Certain measures 
can also be acquired under terminal anaesthesia or post-mortem, such as blood pressure via direct 
arterial cannulation, tissue oxygenation, microcirculatory perfusion in specific beds, and serological and 
histological measures pertaining to end organ function. In depth assessment of lung function 
measurements using technology such as the FlexiVent (SIREQ) can also be used under terminal 
anaesthesia for the assessment of sepsis induced acute lung injury. 
Many of these realtime monitoring technologies generate high fidelity data, much of which is typically 
underused. Interdisciplinary collaboration with bioengineering and mathematics can help to make 
more of the data acquired. For example, the extraction of heart rate variability  or other detailed 
cardiovascular changes [103-105] [106] [107] can be generated from preclinical blood pressure or ECG 
waveforms and can be combined with inflammatory biomarkers, to build a more detailed picture of the 
physiological status of the animal. Reassuringly, such  interdisciplinary analytical approaches have 
already led to the successful development of prognostic systems in patients [108].  
In summary, with careful incorporation of more humane endpoints, these experimental techniques 
when used individually or in combination, generate quantitative measures/biomarkers which can allow 
discrete mechanistic questions to be answered. In turn, the knowledge of such biomarkers could 
improve future clinical studies identifying more detail measures pertaining to efficacy and safety, to be 
incorporated as clinical trial endpoints. We propose that such quantitative measures acquired at 
specific time points better fulfil the harm:benefit assessment, compared with mortality end point 
models. 
Take home message : Circulatory disturbances in sepsis 
Animal models may still be required to validate safety and efficacy of new therapeutic entities 
that target the cardiovascular system. Several minimally invasive technologies and in vitro 
models are available which can help reduce, refine and replace animal experiments. Realtime 
monitoring technologies can encourage use of scientifically valuable, humane endpoints, 




What needs to change? Part 2 – Better use of clinical data 
Preclinical outcomes-clinical validation: Bridging the gap (valley of death?) 
We propose that pre-clinical research and development in sepsis needs to ‘re-tool’, to recognise that 
current, animal model, driven approaches lack sufficient predictive validity to affect successful clinical 
translation. Two things need to change: firstly, research focus needs to be redirected to address the 
key clinical need for biomarkers that enable early identification of sepsis and effective stratification of 
patient subtypes for treatment regimens; secondly, more predictive model systems need to be 
developed.  
 
Figure 1 The key features of a ‘humanised’ drug discovery process (Bioindustry Association/Medicines 
Discovery Catapult report, UK 2018) 
The 2018 joint report from the Bioindustry Association and the Medicines Discovery Catapult  [109] 
examined the current state of drug discovery in the UK and emphasised the highly challenging issue of 
poor translation. They proposed a radical change in approach that centred on humanising discovery 
through better use of patient biomarker data and the development of advanced human-based in vitro 
model systems. They argue that effective drug development requires libraries of mechanistic models 
to be developed that reflect the heterogeneity of human disease. No one would present that this is 
easy or that it can be achieved overnight but the ongoing crisis in translation needs to be addressed 
and a radical change in approach is needed. Critical selection of targets and expected outcomes are 
crucial, and one cannot just rely on the validity of a one-fits-all preclinical model. 
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Figure 1, taken from the report, nicely illustrates how the three critical components of this approach 
using patient derived targets and biomarkers, humanised models and high content stratified clinical 
trials, come together. Central and critical to this approach is a joined-up mechanism for data sharing, 
with all stakeholders working together to achieve translational benefit. 
So, how would this work in sepsis research? Clearly, this needs to start with the identification of robust, 
biomarkers of disease. Currently, vast amounts of data are collected from patients and this needs to be 
standardised, collated, appropriately labelled, deidentified and analysed; not simply biomarker data but 
treatment and outcome data too. Additional approaches such as genome wide association studies need 
to be applied as well as any new emerging technologies and together these can help better identify 
druggable targets [110, 111]. Unsupervised machine learning approaches can help identify patient 
subgroups through clustering patterns of multiple input variables. We need to paint a comprehensive 
picture of each patient from their initial presentation through diagnosis, treatment and long-term 
outcome – including indices of quality of life. Progress is already being made in this area with the 
development of early warning scores derived from annotated health records [112, 113] [114] [16, 79] 
but systems like this need to be implemented across the whole healthcare network as part of an 
integrated data sciences approach. Such a shift in approach will require significant investment and we, 
perhaps provocatively, suggest that some funding currently directed towards use of existing animal 
models of sepsis could be redirected to cover this. 
Where animals may still be required would be the identification of detailed biomarkers pertaining to 
on-target and off-target effects of new therapeutic entities. Through mechanistic investigation, such 
biomarkers could be incorporated into clinical trials to provide more detailed end points which may 
address the high risk of failure in reaching primary endpoints such as mortality. Such investigations may 
not necessarily require sepsis models. Joined up research studies which demonstrate the clinical 
relevance of specific animal models will become increasing possible with the rise in available clinical 









Take home message : Top down approach to sepsis research 
Take Home Message: A shift of focus, from animal-based approaches to one that places more 
emphasis on human clinical data will benefit more patients in the short term and identify new 
therapeutic targets for drug development in the longer term. 
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What needs to change? Part 3 – developing more predictive preclinical models. 
We have outlined a proposal to move away from diseased focused models (face validity) to mechanistic 
models (construct validity), but this can only work if sepsis disease mechanisms are better understood. 
It could be argued that pre-clinical disease models are needed in order to elucidate these mechanisms, 
and we recognise that this is a valid argument. We propose that another approach should also be 
explored; one where biomarkers identified from clinical electronic health record data (outlined above) 
are used to target the development of new preclinical models with a purely mechanistic focus. We 
argue that this will accelerate clinical development, whilst reducing the welfare burden on animals.  
To illustrate our proposed ‘re-tooling’ of sepsis research we have produced a simple scheme (Figure 2). 
Applied research (where a specific disease target mechanism is known) can involve development of 
new therapeutic entities or repurposing of existing pharmacological agents, previously developed for a 
different disease, but which involves the same mechanistic pathway or target. Here, as described 
above, the key information to enable progression into clinical assessment are: 
• target engagement (e.g. efficacy) at a given plasma level (requiring evaluation of the 
absorption, distribution, metabolism and excretion [ADME] profile)  
• safety (as determined by standard regulatory tests)[116].   
We argue that target engagement assessment does not necessitate an animal model of disease (face 
validity) but rather a model that is optimised to report engagement at the specific target (mechanistic 
model; construct validity). Indeed, it may not be necessary for this model to resemble sepsis at all. This 
relies on the target being robust and selected based on clear evidence from clinical data and should be 
subject to a patient risk/benefit assessment (where the risk of initiating a first in human trial is assessed 






Figure 2 – schematic of proposed pathway for a ‘re-tooled’ drug-discovery programme for a new 
pharmacological intervention for sepsis. 
 
The pre-clinical model(s) that best enables robust decision making and rapid transition into clinical 
assessment should be used and these may be very different from those used currently. In this scheme 
an animal model of sepsis is only necessary in circumstances where the patient risk/benefit analysis or 
regulatory bodies, require it. Here, we suggest that the most translational sepsis model is used e.g. an 
animal model with full intensive care unit (ICU) support  [117]. 
Modelling sepsis in animals – mimicking the clinical setting 
Due to the complex multi-system pathogenesis of sepsis, animal models modelling the syndrome 
should ideally aim to replicate those conditions experienced by sepsis patients in ICU. These include 
pharmacological and supportive interventions (e.g. vasopressors, enteral or parenteral nutrition, 
resuscitation with intravascular fluids, sedation, mechanical ventilation) with parallel clinical 
assessments (continuous hemodynamic monitoring, discontinuous serological sampling, blood 
biochemistry, qualitative observation). 
Use of routine supportive clinical interventions, including fluid resuscitation and antimicrobial therapy 
is considered important when modelling sepsis. However, use of these interventions is not always 
reported [88]. Hypovolemia is observed in clinical sepsis and fluid resuscitation is always recommended 
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in animal models for both  scientific and welfare reasons [20]. If fluid resuscitation is not performed, it 
becomes challenging to dissociate scientific outcomes of the sepsis model per se, from those that result 
from hypovolemia.    There are now guidelines in place for resuscitation regimes in the preclinical setting 
in an effort to standardise this step [88]. Whether adherence to such recommendations impacts 
positively on clinical translatability, remains to be demonstrated. 
Use of antimicrobial therapy in preclinical studies has also been debated. On the one hand, including 
antimicrobials would better mimic the clinical situation. On the other hand, it may interfere with the 
model progression, potentially obscuring the elucidation of cellular or molecular mechanisms. The use 
of antimicrobial therapy has been investigated in numerous animal models [118-120] and there are 
existing recommendations on how use of antibiotics might enhance the clinical translation of preclinical 
data [88]. However, antimicrobial use must be scientifically justified, and antibiotic stewardship should 
always be prioritised to avoid contributing to antimicrobial resistance development both within and 
outside, animal research units [121]. 
These implementations can be challenging when using small laboratory animals, particularly rodents, 
due to considerable hemodynamic profile differences (very high circulation times and limited blood 
volumes in comparisons to larger mammals and humans) and complexity of microsurgical 
interventions. However, adaptation and miniaturization of monitoring equipment for use in smaller 
laboratory animals is now making it possible (e.g. specialised mechanical “lung-protective” ventilators 
that minimise the risk of injury through improvements in tidal volume and positive end-expiratory 
pressure). However, innate high resilience to ischemic-reperfusion injury, poor thermogenesis and 
physiological limitations for repetitive sampling, remain important challenges in rodents. Nevertheless, 
mechanistic and early-phase discovery studies in rodents should, wherever possible, implement 
extensive physiological monitoring (particularly MABP and body temperature) and fluid support/ 
resuscitation, to better mimic the clinical situation [86] 
Due to these challenges, the use of a larger animals in such ICU settings, particularly the porcine shock 
model, has increasingly been used. A larger species allows the use of existing testing of new clinical 
monitoring equipment, repetitive blood sampling (valuable for differential and blood gas analysis) 
supporting better titration of dosing in accordance with routine point-of-care readouts and biomarkers. 
They also mirror the thermogenesis response to stress and the systemic energetic failure associated 
with septic shock (circulatory shock). Furthermore, there is an increasing need for mid-longer term 
understanding of the pathophysiology of sepsis and how proposed interventions impact on sepsis 
patients during their stay in ICU, particularly on the onset and progression of organ dysfunction. Models 
in which it is possible to perform longer-term studies, with full ICU support are therefore needed. 
However, there are considerable constraints related to infrastructure and equipment, staffing and 
funding. In addition, current equipment and protocols make maintaining animals in an ICU setting 
challenging due to complications related to mechanical ventilation - the maximum duration is  ~15-24h 
in rodents 100h in pigs, with pigs being particularly susceptible to develop impaired lung function 
associated with pronounced acute pulmonary hypertension [122, 123].  
The implementation of pre-clinical ICU-mimicking studies, with an intensive monitoring and a care 
program, are also critically important from an animal welfare perspective. As stated previously, the 
intrinsically severe nature of many sepsis models, and the impact that this has on the validity and quality 
of the experimental data raises significant ethical issues. For example, sympatho-adrenal responses to 
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stress result in increased circulating levels of catecholamines which will trigger tachycardia and 
hypertension, pain will also modulate the HPA axis affecting cortisol and growth hormone release, 
among others effects on homeostasis [124] [125]. 
Larger animal ICU paradigms also allow for studies to be adaptive in nature, responding to real time 
biomarkers and this more closely resembles adaptive approaches in human clinical trial design [126]. 
However, this is not always possible in smaller rodent models which tend to use predefined time 
courses and intervention protocols and where repeat blood samples will be limited by small circulating 
volume. 
The establishment of comprehensive, clinically relevant care/welfare and experimental outcomes 
remains a significant challenge in sepsis modelling, and ICU monitoring settings will support better 




Sepsis can be devastating for patients and their families, even those that survive can experience long 
term health issues. Clearly, research is needed to find new and better ways to combat this; we do not 
dispute this. In this paper we have described some of the reasons why current research approaches 
have mostly failed to translate into clinical benefit and offer a deliberately provocative alternative 
approach. We suggest that sepsis research funding could, in the short term, be redirected towards 
better characterisation of human patient data linked to outcome such as proteomics/metabolomics 
and other biomarker studies in patients. We suggest that these data will identify new therapeutic 
targets for pre-clinical research or identify more sensitive and specific diagnostics or biomarkers for 
patient stratification. Where appropriate, targets can be tested using mechanistic animal models, which 
may or may not be based on traditional animal models of sepsis. Where a pre-clinical proof of concept 
efficacy study is justified, we propose that large animal models with full ICU support may have the 
greatest translational potential. Whilst we do not dispute the value of animal models in medical 
research, we assert that the value of any model is diminished if it is stretched beyond the point where 
it is fit for purpose. A harm:benefit assessment should always be conducted prior to any study and 
Take home message : Mimicking the clinical setting 
 Current pre-clinical approaches are not delivering for sepsis patients. We propose the concept 
that a single animal model could be the ‘gold standard’ predictor of clinical success should be 
abandoned. Mechanistic models, derived from human clinical data, with a focus on target 
engagement rather than clinical phenotype should be more predictive. If disease (face 
validity) models are required, these should mimic human clinical ICU settings. 
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based on pre-existing clinical or preclinical evidence. We hope that this review stimulates debate and 
encourages new collaborations between basic and clinical researchers and ultimately paves the way for 
improved outcomes for sepsis patients. 
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Summary of key messages: 
Experimental design Experimental sepsis research must be designed, 
conducted and reported in such a way to 
minimise bias and to maximise the potential for 
replication.  
3Rs importance of harm:benefit assessement Harm-benefit impact assessment and full 
scientific justification should be at the forefront 
of any new studies involving research animals. 
Harm relates to welfare experience of animal 
whilst benefit relates to value of scientific data. 
Data should be interpreted in the context of what 
the model can deliver, avoiding over translation. 
3Rs impact of construct validity models Focusing on construct rather than face validity, 
has the same potential to increase clinical 
translation, but with reduced levels of animal 
suffering. 
Mechanistic models of inflammatory and 
immune pathways and enhancing the 
translational gap 
As our knowledge of the innate immune 
responses in sepsis increases, new therapeutic 
targets and new potential biomarkers to 
measure sepsis progression and response to 
therapy are emerging. These include metabolic 
markers that underlie trained immunity and 
immune cell activation and biomarkers of 
inflammasome activation which could be 
mechanistically investigated in preclinical 
models. As tools and technologies for systems 
biology and high throughput screening advance, 
there can be an increased use of humans and 
human –derived tissue for sepsis research 
models. Development of more sophisticated 
models will enable the identification of new 
immune mechanisms that can be translated into 
new diagnostic and therapeutic practice. 
Cardiovascular monitoring strategies that 
support the 3Rs 
Animal models may still be required to validate 
safety and efficacy of new therapeutic entities 
that target the cardiovascular system. Several 
minimally invasive technologies and in vitro 
models are available which can help reduce, 
refine and replace animal experiments. Realtime 
monitoring technologies can encourage use of 
scientifically valuable, humane endpoints, whilst 
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avoiding mortality endpoints. Such endpoints 
may be incorporated into future clinical studies. 
Mimicking the clinical setting where regulators 
require sepsis to be modelled 
Current pre-clinical approaches are not 
delivering for sepsis patients. We propose the 
concept that a single animal model could be the 
‘gold standard’ predictor of clinical success 
should be abandoned. Mechanistic models, 
derived from human clinical data, with a focus 
on target engagement rather than clinical 
phenotype should be more predictive. If disease 
(face validity) models are required, these should 
mimic human clinical ICU settings. 
Top down approach to sepsis research A shift of focus, from animal-based approaches 
to one that places more emphasis on human 
clinical data will benefit more patients in the 
short term and identify new therapeutic targets 
for drug development in the longer term. 
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